taxans induced neuropathy.
Conditions
Interventions
Intervention 1: Intervention group: patients will be administered Memantine orally with increasing doses: 5 mg/day for 3 days
then 10 mg/ day for 3 days
then 15 mg/day for 3 days and at the end 20 mg/day for 8 weeks. Intervention 2: Control group: No medication will be received by them.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Women over the age of 18 years old who are diagnosed with breast cancer and will be treated with the AC-T regimen (with docetaxol)
Exclusion criteria
Exclusion criteria: Breast cancer with stage IV at the time of diagnosis Patients with hypertension severe cardiac insufficiency diabetes Type I and II Peripheral vascular diseases treatment with specific drugs including Amantadine, ketamine, dextromethorphan,L-Dopa, dopaminergic, anticholinergic agonists,barbituric, neuroleptic, IMAO, antispastic agents, dantrolene or baclofen, phenytoin, cimetidine, ranitidine, procainamide , quinidine, quinine, nicotine, hydrochlorothiazide, warfarin alcohol addiction pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neuropathy severity. Timepoint: At baseline and two months, three months and six months after intervention. Method of measurement: McGill pain questionnaire , Neuropathic Pain in 4 questions , Neuropathic Pain Symptom Inventory and Common Terminology Criteria for Adverse Events(CTCAE ). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaba Ghaffary
Tabriz University of Medical Sciences
Outcome results
None listed